🔗 Share this article

As the US undertakes sweeping adjustments to its immunization recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid vaccines in the pandemic and has zeroed in on potential deaths following COVID-19 immunization in her recent position at the FDA.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to reveal sweeping changes to the pediatric immunization program in December, aligning the US with the Danish immunization schedule, it is understood – a significant shift that would place the US out of alignment with much of the global community with no evidence for benefit. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has repeatedly called for halting some pediatric shot schedules in the US so as to align more similar to the Danish model, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Background

The appointee has no apparent experience in pharmaceutical research, oversight or administrative roles, which has been standard for previous heads of the biologics center. She has served at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a major agency. She has no expertise in drug approvals.”

Past directors of CBER would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that previous people who led CBER have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division authorizes a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and all of those must be looked after,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial management component to the role, which oversees in excess of 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” she said.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s qualifications and whether this assignment represents more teamwork among agency officials on immunizations, a spokesperson responded that the “questions rely on inaccurate assumptions”.

“Her resume aligns with the responsibilities of her position,” the representative explained, citing the months Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious one-day medication authorization process that allegedly concerned her predecessors. “By what process are these therapies being selected for this expedited pathway? Who takes the decisions?” Dr. Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards less stringent oversight of most medications, aside from immunizations.”

Documented Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if problematic, past, critics said. She authored a research paper using non-validated crowd-sourced reports to estimate the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership featured revising rules for recently developed shots and discontinuing “unnecessary” immunizations, she stated following the vote on a online show. At the FDA, Høeg has reportedly floated the idea of excluding teenage boys from receiving Covid vaccinations.

“She’s an all-around true believer who starts off with her conclusions and works backwards to fit the science in a very deceptive, dishonest way,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|